Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease

Gut

Volumn 58, Issue 6, 2009, Pages 790-798

  Shteingart, S ^a   Rapoport, M ^a   Grodzovski, I ^a   Sabag, O ^a   Lichtenstein, M ^a   Eavri, R ^a   Lorberboum Galski, H ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DEXTRAN SULFATE; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; PHOSPHATE BUFFERED SALINE; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RNA ISOLATION; T LYMPHOCYTE; UPREGULATION;

ACUTE DISEASE; ANIMALS; CASPASE 3; COLITIS; COLON; DEXTRAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENES, BCL-2; GENETIC ENGINEERING; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEUTROPHILS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 66649118293     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.153981     Document Type: Article

References (37)

1. Waldmann TA. The interleukin-2 receptor. J Biol Chem 1991;266:2681-2684 (Pubitemid 21909116)
2. Morris JC, Waldmann TA. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000;59(Suppl 1):i109-14.
3. Papadakis KA, Targan SR. Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin N Am 1999;28:283-296 (Pubitemid 29306480)
4. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin N Am 1999;28:255-81, vii. (Pubitemid 29306479)
5. Podolsky DK. Inflammatory bowel disease. New Engl J Med 2002;347:417-429
6. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702. (Pubitemid 20069706)
7. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nature Rev 2006;5:197-209. (Pubitemid 43336033)
8. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-237 (Pubitemid 46706511)
9. Aqeilan R, Kedar R, Ben-Yehudah A, et al. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J 2003;370:129-140 (Pubitemid 36262022)
10. Aqeilan R, Yarkoni S, Lorberboum-Galski H. Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett 1999;457:271-276 (Pubitemid 29401941)
11. Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 2000;5:531-542 (Pubitemid 32182551)
12. Ben-Yehudah A, Aqeilan R, Robashkevich D, et al. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 2003;9:1179-1190 (Pubitemid 36323728)
13. Lichtenstein M, Ben-Yehudah A, Belostotsky R, et al. Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma. Int J Oncol 2005;27:143-148
14. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122:1428-1441 (Pubitemid 34465184)
15. Bradley PP, Priebat DA, Christensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-209 (Pubitemid 12171880)
16. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21-26
17. Mizoguchi A, Mizoguchi E, Chiba C, et al. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med 1996;183:847-856 (Pubitemid 26113957)
18. Shanahan F, Duerr RH, Rotter JI, et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992;103:456-461
19. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549. (Pubitemid 34293433)
20. Dieleman LA, Ridwan BU, Tennyson GS, et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994;107:1643-1652 (Pubitemid 24357616)
21. Kim TW, Seo JN, Suh YH, et al. Involvement of lymphocytes in dextran sulfate sodium-induced experimental colitis. World J Gastroenterol 2006;12:302-305 (Pubitemid 43336932)
22. Shintani N, Nakajima T, Okamoto T, et al. Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action. Gen Pharmacol 1998;31:477-481 (Pubitemid 28398878)
23. Fantini MC, Becker C, Tubbe I, et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006;55:671-680
24. Powrie F. Immune regulation in the intestine: a balancing act between effector and regulatory T cell responses. Ann NY Acad Sci 2004;1029:132-141 (Pubitemid 40298524)
25. Yu QT, Saruta M, Avanesyan A, et al. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2007;13:191-199 (Pubitemid 46806228)
26. Rachmilewitz D, Karmeli F, Shteingart S, et al. Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. Inflamm Bowel Dis 2006;12:339-345 (Pubitemid 43756193)
27. Edelblum KL, Yan F, Yamaoka T, et al. Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. Inflamm Bowel Dis 2006;12:413-424 (Pubitemid 43756203)
28. Bu P, Keshavarzian A, Stone DD, et al. Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J Immunol 2001;166:6399-6403 (Pubitemid 32440774)
29. Itoh J, de La Motte C, Strong SA, et al. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001;49:35-41. (Pubitemid 32601877)
30. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-1090 (Pubitemid 29328123)
31. Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut 2004;53:1556-1558 (Pubitemid 39434092)
32. Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12(Suppl 1):S15-21. (Pubitemid 43068430)
33. Pfister K, Wittig BM, Jungling B, et al. The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice. Int J Colorect Dis 2002;17:77-84. (Pubitemid 36067752)
34. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-135
35. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-3477
36. Sladden MJ, Clarke PJ, Wettenhall J. Infliximab-induced palmoplantar pustulosis in a patient with Crohn disease. Arch Dermatol 2007;143:1449. (Pubitemid 350146282)
37. Neurath MF, Finotto S, Fuss I, et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001;22:21-26 (Pubitemid 32675276)